Chester County News and Community Website
BERWYN, PA — Panavance Therapeutics Inc. has announced groundbreaking findings this week, demonstrating the potential of their investigational drug, misetionamide (GP-2250), to tackle various forms of cancer by directly inhibiting …
Panavance Therapeutics Unveils Promising Data on Misetionamide’s Dual Cancer Targeting Mechanism Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has unveiled encouraging preliminary data from the Phase 1 portion of its OCU410 ArMaDa clinical trial, aimed at treating geographic atrophy (GA) secondary …
Ocugen Reports Promising Results from OCU410 ArMaDa Trial for Geographic Atrophy Read More
WAYNE, PA — Palvella Therapeutics, Inc. has announced the commencement of dosing in its Phase 3 SELVA trial, aimed at evaluating QTORIN™ 3.9% rapamycin anhydrous gel for treating microcystic lymphatic malformations …
Palvella Therapeutics Begins Phase 3 Trial for Microcystic Lymphatic Malformations Treatment Read More
WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has announced the enrollment of the first patient in a new clinical study focused on the Barrigel™ rectal spacer. This major milestone marks …
Teleflex Inc. Enrolls First Patient in Barrigel™ Rectal Spacer Study Read More
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) is gearing up to showcase critical research at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) conference, scheduled from October 29 to …
Annovis Bio to Present Key Alzheimer’s Research at CTAD Conference Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced a significant development in its efforts to treat Stargardt disease, as the Data and Safety Monitoring Board (DSMB) has greenlit the …
Ocugen Advances Stargardt Disease Trial with Promising Gene Therapy Read More WAYNE, PA — Teleflex Incorporated (NYSE: TFX) is set to host a conference call on October 31, 2024, at 8:00 a.m. Eastern Time to discuss its third quarter financial results …
Teleflex Announces Third Quarter Financial Call and Highlights Promising Data on Prostate Cancer Treatment Read More MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced a successful outcome from its recent End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). The FDA has given …
Annovis Bio Advances Alzheimer’s Treatment with FDA Approval for Phase 3 Trials Read More BERWYN, PA — Panavance Therapeutics Inc. announced interim results from its Phase 1 clinical trial at the 2024 Visceral Medicine Congress in Leipzig, Germany. The study evaluates the safety and efficacy …
Panavance Unveils Game-Changing Data: A New Hope for Pancreatic Cancer Patients? Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) this week announced a pivotal development as the FDA lifted the clinical hold on its investigational drug application for OCU200.
FDA Greenlights Ocugen’s Revolutionary Eye Treatment: What It Means for Vision Care Read More